Annual Results Press Conference 2022
Boehringer Ingelheim presents the results of business development and gives an outlook for the coming year.
Search
GlyT1 Phase II results
Boehringer Ingelheim refocuses Gly-T1 inhibition brain research on schizophrenia
Boehringer Ingelheim - Value Through Innovation
Boehringer Ingelheim is one of the world's leading research-driven pharmaceutical companies with 130 years of experience.
Ileitis prevention vaccination Lawsonia intracellularis pig
Cause, impact and prevention: Learn the essentials about Ileitis
Annual_Report_2022_consolidated-companies_EN
Mechanistic Modeling in Biotherapeutic Drug Development
Mechanistic modeling is revolutionizing biotherapeutic drug development with the goal of getting new medicines to patients faster, more reliably and more cost-effectively.
equine asthma
Fighting Equine Asthma is a crucial step to improving the well-being of many horses worldwide. The right treatment can make a world of difference.
GARC Louis Nel interview on global rabies control
GARC’s Executive Director Professor Louis Nel shares what it takes to fight rabies.
Metabolic Diseases
Metabolic Diseases
Cat vaccination 10 things you should know
Find out how you can keep your feline companion happy and healthy. We’ve answered 10 important questions about cat vaccination, to help you make informed decisions about preserving your cat’s health.
Global Code of Conduct
Boehringer Ingelheim´s Global Code of Conduct
Bridging the gap in Generalized Pustular Psoriasis (GPP)
Emmanuelle Clerisme-Beaty, Head of Clinical Development and Medical Affairs, Dermatology, discusses recently published insights from GPP patients.
Prevention of Schizophrenia
Can schizophrenia be prevented?That’s what investigators are hoping to find out, according to scientists attending the American College of Neuropsychopharmacology (ACNP) in Orlando, Florida.[node:body][node:title]
IPF treatment discussions
Listen to Steve Jones (a person living wih IPF) and Dr. Marlies Wijsenbeek (a leading pulmonologist) discuss the importance of treatment discussions in IPF
Across Cancer Types
Across Cancer Types
SIRPα Cancer Immunology Research
Boehringer Ingelheim scientists are investigating a new target in the innate immune system - signal-regulating protein alpha or SIRPα.
NeO - smart and sustainable vaccines
The reduction in the environmental impact of the new NeO vaccine packaging illustrates Boehringer Ingelheim’s drive for environmental responsibility.
Facts about the INPULSIS™ trials
Facts about the INPULSIS™ trials
Oncology and Cancer Immunology Research
Find out more about our research and development in oncology and cancer immunology.
Empowering all employees
Boehringer Ingelheim has been awarded as a Global Top Employer for the second year in succession
10 tips cat friendly veterinary clinics
Here are 10 simple steps you can take to make feline patients feel at ease at your practice.
Cardiometabolic Research
Read about our patient-centric approach to cardiometabolic disease research.
China pioneers biosecurity report against ASF
Boehringer Ingelheim compiles data from 1,000 swine farms into the first market report on biosecurity. Document sheds light on livestock management and contributes to the fight against African swine fever.
Europe needs a vibrant research eco-system
At this week's EFPIA Days in Brussels, stakeholders will discuss how to re-establish a research-friendly eco-system in Europe.
Beyond the Stigma
Hear first-hand a patient and caregiver’s perspective of living with schizophrenia.